Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Molding Technologies (CMT) Cash & Equivalents (2016 - 2025)

Core Molding Technologies (CMT) has disclosed Cash & Equivalents for 13 consecutive years, with $18.0 million as the latest value for Q3 2023.

  • On a quarterly basis, Cash & Equivalents rose 3443.22% to $18.0 million in Q3 2023 year-over-year; TTM through Sep 2023 was $18.0 million, a 3443.22% increase, with the full-year FY2022 number at $4.2 million, changed N/A from a year prior.
  • Cash & Equivalents was $18.0 million for Q3 2023 at Core Molding Technologies, up from $14.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $18.0 million in Q3 2023 to a low of $114000.0 in Q2 2022.
  • A 5-year average of $4.9 million and a median of $3.6 million in 2020 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 97.96% in 2022, then skyrocketed 12322.81% in 2023.
  • Core Molding Technologies' Cash & Equivalents stood at $533000.0 in 2019, then surged by 675.05% to $4.1 million in 2020, then plummeted by 85.11% to $615000.0 in 2021, then surged by 580.16% to $4.2 million in 2022, then surged by 331.15% to $18.0 million in 2023.
  • Per Business Quant, the three most recent readings for CMT's Cash & Equivalents are $18.0 million (Q3 2023), $14.2 million (Q2 2023), and $4.5 million (Q1 2023).